Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy of Topical Cyclosporine A for Treatment and Prevention of Graft Rejection in Corneal Grafts With Previous Rejection Episodes

This study has been completed.
Information provided by:
Shahid Beheshti University of Medical Sciences Identifier:
First received: December 8, 2009
Last updated: NA
Last verified: April 2006
History: No changes posted
The use of topical Cyclosporine A early after an episode of endothelial graft rejection after penetrating keratoplasty and continuing its administration for 6 months can reduce the course of that episode and recurrence of the rejection.

Condition Intervention Phase
Endothelial Graft Rejection
Drug: Sandimmune
Drug: Artelose
Phase 4

Study Type: Interventional

Resource links provided by NLM:

Further study details as provided by Shahid Beheshti University of Medical Sciences:

Primary Outcome Measures:
  • The rate of rejection after drop sessation [ Time Frame: 3 years ]

Arms Assigned Interventions
Active Comparator: Cyclosporine A 2% Drug: Sandimmune
Placebo Comparator: Artificial tears Drug: Artelose


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Penetrating keratoplasty in eyes without vascularization

Exclusion Criteria:

  • History of previous intraocular surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01028443

Iran, Islamic Republic of
Ophthalmic Research Center
Tehran, Iran, Islamic Republic of, 166666
Ophthalmic Research Center
Tehran, Iran, Islamic Republic of, 16666
Sponsors and Collaborators
Shahid Beheshti University of Medical Sciences
  More Information Identifier: NCT01028443     History of Changes
Other Study ID Numbers: 8546
Study First Received: December 8, 2009
Last Updated: December 8, 2009

Additional relevant MeSH terms:
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors processed this record on May 23, 2017